MARS-GROWTH-CAPITAL
1.9.2021 12:32:05 CEST | Business Wire | Press release
Mitsubishi Group (MUFG) the second largest banking and finance group in the world has injected another $120 million investment into the Mars Growth fund, a 50/50 joint venture owned by MUFG and Liquidity Capital. MUFG has a broader strategic relationship with Liquidity and this latest investment represents their cumulative investment of $220 million to date.
Mars Growth Capital provides debt financing solutions to technology companies in Asia Pacific and Europe. Since its inception one year ago, the fund has recorded exceptional performance through ten transactions to the value of $80 million, executed across Asia, Australia and Europe, with demand exceeding $2 billion during this period.
Through its strategic collaboration with MUFG, Liquidity is focused on revolutionizing the credit underwriting process for the business sector. Recognizing the challenges for high potential companies to secure non-dilutive capital from traditional financial institutions, Liquidity developed DYNAMiCS, a world-first, machine learning platform that can perform fast and thorough, data-driven due diligence on companies to assess their performance and growth potential.
DYNAMiCS uses algorithms to accurately predict future revenues, cash balances and other relevant financial covenants unique to technology business. Each of Liquidity’s four funds, including Mars Growth Fund, use the platform to inform their investment decision making, oftentimes in a process that takes less than 24-hours to complete.
Liquidity Group has provided over $750 million during the last year to over 50 growth companies across USA, Asia Pacific, Europe and the Middle East, including top unicorns such as eToro, Homer, Resident, Infinidat, Acronis, Infra.Market, and others. Its financing ranges from $5 million to $100 million, and is committed to 24-hour due diligence using its first of a kind platform - DYNAMiCS.
Ron Daniel, Liquidity CEO, said: “MUFG's ongoing investment in our funds is a vote of confidence in our technology, capabilities and potential. Mars Growth Capital’s performance to date is a reflection of the strength of our methodology of combining our team’s professional investing expertise with our bespoke DYNAMiCS technology solution. We are excited to continue our ongoing partnership with MUFG, who shares our ethos to support innovative, technology-driven companies across key market segments.”
Rio Hiroshima, who manages Mars Growth Capital’s operations on behalf of MUFG, said, “Since launching the fund just one year ago, we have quickly positioned ourselves as the market leader in growth financing for technology companies across the APAC and EMEA regions. Market demand, coupled with our strong investment performance has enabled us to grow rapidly and increase the value of the fund to $200 million. We are excited to continue our partnership with MUFG as we continue on the same dizzying trajectory into 2022”.
Yaron Primovich, the fund manager on behalf of Liquidity said: "Our partners at MUFG believe in our value proposition, and share our ambitions to be the global leader in growth financing. We hold a unique position in the marketplace because our underwriting platform acts as a data-driven oracle to identify and assess the potential of prospect companies. DYNAMiCS can cut through masses of information to analyse the strength of different business models, end customer behaviours and financial situations, arming us with insights to determine a company's ability to meet future debt repayments.”
"In a post Covid-world, businesses across the globe are on the cusp of even greater levels of innovation and expansion, further fuelling companies' appetite for growth and debt without dilution. We are excited to play a crucial role in helping these companies optimise on this opportunity”.
In addition, Mars Growth Capital has registered high levels of demand from hundreds of companies, in less than one year since its formation.
Notes to Editor
About Liquidity
Liquidity was established in 2018 by Ron Daniel, Yaron Sela and Oron Maymon. Liquidity manages $800 million in several funds worldwide. Among the partners in the company are Spark Capital, Meitav Dash and the Mitsubishi Banking Corporation. The company is considered a world leader in business credit management for growth companies using the machine learning technology it has developed. www.liquiditycap.com
Mars Growth is a joint venture between Liquidity Capital and MUFG that offers tech startups a one-of-a-kind funding alternative, enabling them to double down on their hyper-growth without giving up equity. Its trajectory-based funding model allows them to work with startups and growth-stage companies side-by-side, taking on financial risk. Part of the Liquidity funds arm, Mars Growth invests in SaaS providers that demonstrate over $3M in ARR and 30% year-over-year growth, with an average ticket size of $3M-$100M.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005448/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom